Synmosa Biopharma - Asset Resilience Ratio
Synmosa Biopharma (4114) has an Asset Resilience Ratio of 7.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Synmosa Biopharma (4114) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Synmosa Biopharma's Asset Resilience Ratio has changed over time. See shareholders equity of Synmosa Biopharma for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Synmosa Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4114 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.04 Billion | 7.44% |
| Total Liquid Assets | NT$1.04 Billion | 7.44% |
Asset Resilience Insights
- Limited Liquidity: Synmosa Biopharma maintains only 7.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Synmosa Biopharma Industry Peers by Asset Resilience Ratio
Compare Synmosa Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277 |
Drug Manufacturers - Specialty & Generic | 31.63% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 3.29% |
Annual Asset Resilience Ratio for Synmosa Biopharma (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Synmosa Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.44% | NT$1.04 Billion ≈ $32.77 Million |
NT$13.99 Billion ≈ $440.61 Million |
+1.75pp |
| 2024-12-31 | 5.68% | NT$699.34 Million ≈ $22.03 Million |
NT$12.30 Billion ≈ $387.65 Million |
-0.59pp |
| 2023-12-31 | 6.28% | NT$736.33 Million ≈ $23.20 Million |
NT$11.73 Billion ≈ $369.51 Million |
+3.32pp |
| 2022-12-31 | 2.96% | NT$331.68 Million ≈ $10.45 Million |
NT$11.20 Billion ≈ $352.94 Million |
+1.75pp |
| 2021-12-31 | 1.21% | NT$124.96 Million ≈ $3.94 Million |
NT$10.32 Billion ≈ $325.04 Million |
+0.18pp |
| 2020-12-31 | 1.03% | NT$107.01 Million ≈ $3.37 Million |
NT$10.38 Billion ≈ $326.95 Million |
-0.17pp |
| 2019-12-31 | 1.20% | NT$105.00 Million ≈ $3.31 Million |
NT$8.73 Billion ≈ $275.04 Million |
+1.14pp |
| 2018-12-31 | 0.07% | NT$5.05 Million ≈ $159.10K |
NT$7.54 Billion ≈ $237.70 Million |
-0.37pp |
| 2017-12-31 | 0.44% | NT$32.86 Million ≈ $1.04 Million |
NT$7.50 Billion ≈ $236.41 Million |
-0.01pp |
| 2016-12-31 | 0.45% | NT$30.52 Million ≈ $961.64K |
NT$6.79 Billion ≈ $213.90 Million |
-- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more